Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities

Molecular Pharmacology

Volumn 62, Issue 4, 2002, Pages 873-880

  Umemura, Ken ^a,d   Mizushima, Tomoko ^a   Katayama, Hajime ^b   Kiryu, Yoshimitsu ^b   Yamori, Takao ^c   Andoh, Toshiwo ^a  

^a SOKA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CIRCULAR DNA; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; GYRASE INHIBITOR; HYDROXYL GROUP; KINETOPLAST DNA; PYRAZOLO[1,5 A]INDOLE DERIVATIVE; PYRAZOLONE DERIVATIVE; TENIPOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DNA CLEAVAGE; DNA STRAND BREAKAGE; EHRLICH ASCITES TUMOR; ENZYME INHIBITION; HUMAN; HUMAN CELL; INSECT CELL; NONHUMAN; PRIORITY JOURNAL;

CELL DIVISION; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; ENZYME INHIBITORS; HUMANS; INDOLES; PYRAZOLES; TUMOR CELLS, CULTURED;

EID: 0036784064     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.4.873     Document Type: Article

References (33)

1. Andoh T and Ishida R (1998) Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta 1400:155-171.
2. Chen AY and Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191-218.
3. Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, and Mirabelli CK (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent Merbarone. Cancer Res 49:2578-2583.
4. Fortune JM and Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem 273:17643-17650.
5. Hsiang Y-H, Hertzberg R, Hecht S, and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878.
6. Hsiang Y-H and Liu LF (1988) Identification of mammarian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726.
7. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsugi KR and Andoh T (1991) Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51:4909-4916.
8. Ishii K, Hasegawa T, Fujisawa K, and Andoh T (1983) Rapid purification and characterization of DNA topoisomerase I from cultured mouse mammary carcinoma FM3A cells. J Biol Chem 258:12728-12732.
9. Jensen PB, Jensen PS, Demant EJ, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindelov L, Westergaard O and Hansen HH (1991) Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res 51:5093-5099.
10. Katayama H, Kawada Y, Kaneko K, Oshiyama T, and Takatsu N (1999) Synthetic inhibitors of DNA topoisomerase I and II. Chem Pharm Bull 47:48-53.
11. Katayama H, Kiryu Y, Kaneko K, and Ohshima R (2000) Anti-cancer activities of pyrazolo[1,5-a]indole derivatives. Chem Pharm Bull 48:1628-1633.
12. Kaufmann SH and Svingen PA (1999) Immunoblot analysis and band depletion assays, in Methods in Molecular Biology, Vol. 94: DNA Topoisomerase Protocols, Part I: DNA Topology and Enzymes (Bjornsti M-A and Osheroff N eds) pp 253-268, Humana Press, Clifton, New Jersey.
13. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766.
14. Nelson EM, Tewey KM, and Liu LF (1984) Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by m-AMSA. Proc Natl Acad Sci USA 81:1361-1365.
15. Perrin D, van Hille B, Barret JM, Kruczynski A, Etievant C, Imbert T, and Hill BT (2000) F11782, a novel non-intercalating dual inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 59:807-819.
16. Pommier Y, Covey JM, Kerrigan D, Markovits J, and Pham R (1987) DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res 15:6713-6731.
17. Pommier Y, Pourquier P, Fan Y, and Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzymes. Biochim Biophys Acta 1400:83-105.
18. Riou JF, Fosse P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, Saucier JM, Bisagni E, and Lavelle F (1993) Intoplicine (RP 60475) and its derivatives, a new class of antitumour agents inhibiting both topoisomerase I and II activities. Cancer Res 53:5987-5993.
19. Roca J, Ishida R, Berger JM, Andoh T, and Wang JC (1994) Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91:1781-1785.
20. Sato S, Fukuda Y, Nakagawa R, Tsuji T, Umemura K, and Andoh T (2000) Inhibition of DNA topoisomerases by nidulalin A derivatives. Biol Pharm Bull 23:511-512.
21. Sehested M and Jensen PB (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51:879-886.
22. Shapiro TA, Klein VA, and Englund PT (1999) Isolation of kinetoplast DNA, in Methods in Molecular Biology, Vol. 94: DNA Topoisomerase Protocols, Part I: DNA Topology and Enzymes (Bjornsti M-A and Osheroff N eds) pp 61-67, Humana Press, Clifton, New Jersey.
23. Simpson AM and Simpson L (1974) Isolation and characterization of kinetoplast DNA networks and minicircles from Crithidia fasciculata. J Protozool 21:774-781.
24. Sorensen BS, Jensen PB, Sehested M, Jensen PS, Kjeldsen E, Nielsen OF, and Alsner J (1994) Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. Biochem Pharmacol 47:2105-2110.
25. Stewart L and Champoux JJ (2001) Assaying DNA topoisomerase I relaxation activity, in Methods in Molecular Biology, Vol. 94: DNA Topoisomerase Protocols, Part II: Enzymology and Drugs (Bjornsti M-A and Osheroff N eds) pp 1-11, Humana Press, Clifton, New Jersey.
26. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T and Tsuruo T (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50:6925-6930.
27. Tanabe K, Ikegami Y, Ishida R, and Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51:4903-4908.
28. Utsugi T, Aoyagi K, Asao T, Okasaki Y, Aoyagi Y, Sano M, Wierzba K, and Yamada Y (1997) Antitumour activity of a novel quinolone derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res 88:992-1002.
29. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
30. Wang JC (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q Rev Biophys 31:107-144.
31. Watt PM and Hickson ID (1994) Structure and function of type II DNA topoisomerases. Biochem J 303:681-695.
32. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, et al. (1999) Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 59:4042-4049.
33. Yanase K, Sugimoto Y, Andoh T, and Tsuruo T (1999) Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance. Int J Cancer 81:134-140.